In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.

The pharma giant has received the CDSCO nod to import sodium zirconium cyclosilicate powder for oral suspension (Lokelma) in ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

In the closing of the recent trading day, Astrazeneca (AZN) stood at $77.47, denoting a -0.63% change from the preceding trading day.

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...

Retail investors have reduced their stakes in 63 small and midcap stocks, which saw declines between 61% and 20% in 2025. The ...

Our writer examines the losses that global stock markets have suffered and ways UK investors can prepare to shield themselves ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

Sun Pharma has made its play just three months after Checkpoint won FDA approval for PD-L1 inhibitor Unloxcyt (cosibelimab) ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...